Orion's partner discontinues development of levosimendan (Simdax) in the US
27-Apr-2007
Simdax will remain available in the markets where it already has been approved. The product has marketing authorisations or submitted applications in more than 40 countries.
Under a renewed licensing agreement concluded in April 2004, Abbott took over the development programme of the intravenously administered formulation of levosimendan and received also extended marketing rights to the product.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.